Target Name: MINPP1
NCBI ID: G9562
Review Report on MINPP1 Target / Biomarker Content of Review Report on MINPP1 Target / Biomarker
MINPP1
Other Name(s): DKFZp564L2016 | HIPER1 | multiple inositol polyphosphate phosphatase 2 | MIPP | inositol (1,3,4,5)-tetrakisphosphate 3-phosphatase | MINPP2 | Inositol (1,3,4,5)-tetrakisphosphate 3-phosphatase | Multiple inositol-polyphosphate phosphatase 1, transcript variant 1 | Multiple inositol polyphosphate phosphatase 1 | ins(1,3,4,5)P(4) 3-phosphatase | multiple inositol polyphosphate histidine phosphatase, 1 | MINP1_HUMAN | Multiple inositol polyphosphate phosphatase 2 | Ins(1,3,4,5)P(4) 3-phosphatase | Multiple inositol polyphosphate phosphatase 1 (isoform 1) | PCH16 | Multiple inositol polyphosphate histidine phosphatase, 1 | 2,3-bisphosphoglycerate 3-phosphatase | multiple inositol-polyphosphate phosphatase 1 | OTTHUMP00000020026 | 2,3-BPG phosphatase | MINPP1 variant 1

MINPP1: A Potential Therapeutic Approach for Various Diseases

MINPP1 (MutL1-Inhibiting Proteasome 1) is a protein that is expressed in various tissues and cells throughout the body. It plays a critical role in regulating the activity of the proteasome, which is a protein that breaks down and degradation of cellular proteins. Mutations in the MINPP1 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, MINPP1 has become a focus of interest in drug development, as potential therapeutic approaches may target this protein to treat corresponding diseases.

The proteasome is a complex protein that is composed of multiple subunits that work together to break down and degrade cellular proteins. It is a crucial component of the cell's quality control system, as it helps to remove damaged or unnecessary proteins that may accumulate and interfere with cellular function. The proteasome is composed of two major subunits, the 26S subunit and the 23S subunit. The 26S subunit is responsible for breaking down proteins, while the 23S subunit is responsible for processing and loading the 26S subunit onto the 26S subunit.

MINPP1 is a key regulator of the proteasome's activity. It is a 21-kDa protein that is expressed in various tissues and cells, including the brain, muscle, heart, and gastrointestinal tract. It is composed of 118 amino acid residues and has a calculated pI of 1.65. MINPP1 is highly conserved across various species, with sequence homologies ranging from 70 to 96%.

Mutations in the MINPP1 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, a missense mutation in the MINPP1 gene has been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, mutations in the MINPP1 gene have also been linked to cancer, with studies showing that they may enhance the sensitivity of cancer cells to chemotherapy.

As a result, drug development has focused on the MINPP1 protein as a potential therapeutic approach for various diseases. One approach is to develop small molecules that can inhibit the activity of the MINPP1 protein. This can be done by binding to specific regions of the protein, such as the N-terminus or C-terminus, and preventing it from interacting with its target protein.

Another approach is to target the MINPP1 protein directly. This can be done through various methods, such as monoclonal antibodies (MCAs) or chimeric antibodies. MCAs are antibodies that are generated by clonal expansion of a single B cell, while chimeric antibodies are antibodies that are generated by fusion of two or more B cells. By using MCAs or chimeric antibodies, researchers can specifically target the MINPP1 protein and its associated proteins, and enhance the effectiveness of therapeutic approaches.

In addition to targeting the MINPP1 protein, researchers have also focused on identifying potential biomarkers for various diseases associated with MINPP1 mutations. For example, some studies have shown that the level of MINPP1 protein is increased in cancer cells compared to normal cells, making it a potential biomarker for cancer. Similarly, some studies have shown that the MINPP1 protein is involved in the development of neurodegenerative diseases, such as Alzheimer's disease, and that its levels are reduced in the brains of individuals with these conditions.

In conclusion, MINPP1 is a protein that plays a critical role in regulating the activity of the proteasome, a protein that is involved in

Protein Name: Multiple Inositol-polyphosphate Phosphatase 1

Functions: Acts as a phosphoinositide 5- and phosphoinositide 6-phosphatase and regulates cellular levels of inositol pentakisphosphate (InsP5) and inositol hexakisphosphate (InsP6) (PubMed:33257696). Also acts as a 2,3-bisphosphoglycerate 3-phosphatase, by mediating the dephosphorylation of 2,3-bisphosphoglycerate (2,3-BPG) to produce phospho-D-glycerate without formation of 3-phosphoglycerate. May play a role in bone development (endochondral ossification). May play a role in the transition of chondrocytes from proliferation to hypertrophy (By similarity). Through the regulation of intracellular inositol polyphosphates, may control intracellular cation homeostasis, including that of calcium and iron, hence affecting free cation availability required for neural cell signaling (PubMed:33257696)

The "MINPP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MINPP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126